Sunitinib Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Reference Brands: Sutent® (EU & US)
Category:
Oncology Cancer Care
Sunitinib Tablets are oral oncology drugs used for renal cell carcinoma and GIST treatment. Available in 12.5 mg to 50 mg strengths, compliant with EU-GMP and USFDA standards. Ideal for B2B supply, private labeling, and hospital tenders across regulated markets.
Sunitinib is available in Tablet
and strengths such as 12.5 mg, 25 mg, 37.5 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sunitinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sunitinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sunitinib Tablets are oral tyrosine kinase inhibitors used to treat renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg film-coated tablets, our products comply with EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and private labeling, Sunitinib comes with full regulatory documentation including CTD dossiers and bioequivalence data. Trusted by distributors and hospital pharmacies across the US and EU, these tablets ensure consistent quality and efficacy for oncology treatment programs in regulated markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing